76-Year-Old Patient, Not on Antithrombotic Therapy, Presenting to ED After Ground-Level Fall (Glasgow Coma Scale of 15)

March 25, 2022 — According to ARRS’ American Journal of Roentgenology (AJR), antithrombotic therapy was not linked to increased incidence of traumatic intracranial hemorrhage on CT in adult patients, although the therapy did show association with hematoma expansion at follow-up.

“The findings suggest, in patients with good neurological status after ground-level fall, application of a similar strategy for selecting patients for initial head CT, regardless of antithrombotic therapy use,” wrote first author Zeynep Vardar, M.D., at the University of Massachusetts Medical Center in Worcester. “If initial head CT shows traumatic intracranial hemorrhage, early follow-up head CT should be systematically performed in those on antithrombotic therapy though possibly deferred in other patients.”

Vardar and colleagues’ retrospective case-control study included 1,630 patients (693 female, 937 male; mean age, 80 years) who underwent head CT after presenting to the emergency department (ED) with ground-level fall (Glasgow Coma Scale ≥ 14 and no focal neurological deficit) between January 1 and December 31, 2020. Initial head CT examinations were reviewed for traumatic intracranial hemorrhage characteristics and follow-up head CT examinations (performed within 24 hours) were reviewed for hematoma expansion, with clinical outcomes extracted from medical records.

The frequency of intracranial hemorrhage after ground-level fall with good neurological status was not significantly different between patients on antithrombotic therapy and those not on antithrombotic therapy (4.4% vs 3.1% respectively, p = .24). However, hematoma expansion occurred more frequently in patients on antithrombotic therapy (26.2% vs 4.8%, p = .04).

Also noting no significant difference between patients on anticoagulant therapy alone, antiplatelet therapy alone, or both, “the frequency of midline shift and regional mass effect was not significantly different between patients on antithrombotic therapy and control patients,” the authors of this AJR article added.

For more information: www.arrs.org


Related Content

News | Digital Pathology

March 29, 2026 — Leica Microsystems has introduced the Viventis SCAPE light sheet microscope. Viventis SCAPE enables ...

Time April 01, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Cardiac Imaging

March 28, 2026 — When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it ...

Time March 30, 2026
arrow
News | Digital Pathology

March 11, 2026 — Royal Philips has announced the expansion of its digital pathology portfolio with new cloud-enabled ...

Time March 26, 2026
arrow
News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
News | Radiology Imaging

March 23, 2026 — Samsung Medison hsa announced that its U.S. medical imaging businesses, previously operating as ...

Time March 23, 2026
arrow
News | Radiology Business

March 1, 2026 — A new study from the Harvey L. Neiman Health Policy Institute found that practice turnover (i.e ...

Time March 19, 2026
arrow
News | Radiology Education

March 17, 2026 – The Center for Radiology Education (CRE) has announced a nationwide initiative to provide scholarships* ...

Time March 17, 2026
arrow
News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
Subscribe Now